EGFR and non-small cell lung carcinoma: Two independent studies also revealed EGFR-mutated-positive NSCLC had a unique metabotype according to lipidomic profiling in lung pleural effusion (33) and phospholipids of tumor extracellular vesicles were different in gefitinib-resistant NSCLC cells from gefitinib-sensitive NSCLC cells (34).